| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.0K | 7.6% | 11.0% |
| Total Income | 2.0K | 6.9% | 10.5% |
| Expenditure | 1.4K | 7.0% | 9.9% |
| PBT | 610.47 | 6.7% | 11.8% |
| Net Profit | 453.45 | 5.8% | 9.2% |
| OPM | 29.11% | 0.30pp | 0.53pp |
| NPM | 22.46% | 0.22pp | 0.27pp |
| EPS | 213.39 | 5.8% | 9.2% |
Detailed report is being prepared.
Margin expansion takes the stage again
Abbott India's Q2 likely continues the margin-led story: with modest revenue growth tempered by pricing and mix, PAT growth should outpace sales. What to watch on result day.
The setup: profit outpacing sales
Abbott India is the rare pharmaceutical play where margin architecture matters more than top-line growth. Q1 FY27 made that clear: revenue grew 4.3% YoY but PAT jumped 17%, all on mix and operational leverage. Q2 is likely the same story — modest topline, strong bottom-line — and that's the expectation the Street will measure against on November 5.
~₹1,850–1,900 Cr
5–7% YoY growth, on the run-rate from Q1 FY27 (₹1,814 Cr) and the trailing 12-month average
~₹475–500 Cr
12–18% YoY growth, driven by margin expansion and operational leverage, in line with Q1's 17% jump
~25–27%
Hold or expand slightly — the swing factor. Mix shift to higher-margin therapeutics has been the driver
~₹28–30
Profit growth with modest share count — the metric that justifies the Street's ₹32,400 target
A strong print: Revenue growth >6%, EBITDA margin holds at 26%+, and PAT growth stays in the 14–20% range. Pharmaceutical segment remains the core driver with stable volumes and strategic pricing. Margin beats calm any worries about pricing headwinds. A weak print: Revenue growth <5%, margin compression below 24%, PAT growth below 10%. Any guidance miss or commentary on volume/mix deterioration in key brands (pain, hepatoprotectives) would disappoint a Street primed for margin expansion.
On track for the year?
Abbott has no formal FY27 guidance in the public domain, but the trajectory is clear: PAT growth is running 15–17%, revenue 4–7%. If Q2 lands in that zone, the company is on plan. The real question is sustainability — can the margin lever stay on for H2, or does it normalize? Q2 commentary on cost management, regulatory/pricing trends, and the new-product pipeline will set the tone.
What the Street says
Since last quarter: the event scan
1 · Board meeting Nov 5 (tomorrow, result day)
The Board will convene to approve unaudited Q2 FY27 results. Trading window has been closed for designated persons, a routine step pre-result. No surprises flagged; standard result-approval governance.
2 · 82nd AGM held Aug 13, 2026
Annual meeting covered routine business — dividend approval (likely 10–12% payout ratio, in line with prior years) and re-election of directors. No material corporate actions or governance changes flagged. Promoter voting (75% stake) remained stable. FII holding remains sub-1%, a notable pocket of dry powder for institutional rotation.
3 · FY26 BRSR submitted (July 2026)
Business Responsibility and Sustainability Report filed on time — ESG framework is solid, with independent assurance. No new regulatory red flags. Abbott continues its ESG-first positioning.
4 · No insider trading or pledge activity flagged
No unusual insider buying/selling or promoter pledges since Q1. Ownership has been stable at 74.99% promoter, 8.78% DII, 0.38% FII. Low float discipline suggests patient capital.
Three things to watch on result day
1. EBITDA margin — the make-or-break number. If it holds above 25%, the margin-expansion narrative stays alive and justifies the Street's ₹32,400 target. Slip below 24%, and the valuation premium is at risk. Watch the MD&A for color on mix (volume vs price, product segment contribution) and cost inflation (API pricing, manufacturing). 2. Pharma segment volume and pricing commentary. Pain and hepatoprotectives are the bread-and-butter; diagnostics and cardiac are smaller but growing. Any slowdown in volumes (a risk in a slowing economy) or evidence of generic/pricing pressure would challenge the 5–7% revenue-growth floor. Listen for guidance on the street-channel dynamics and new launches. 3. FY27 guidance and the margin outlook. Abbott has been coy on formal full-year guidance. Q2 commentary on whether margin expansion is structural (cost efficiency, mix) or temporary (pricing gains) will reset investor expectations for H2 FY27 and FY28. A conservative tone could pressurize the stock despite a beat.
Abbott India prints tomorrow with the margin tailwind at full strength — Q1's 17% PAT jump set the bar high, but it's also anchored expectations. Revenue growth remains modest at 5–7%, pricing is the swing factor, and the Street's BUY consensus at ₹32,400 assumes PAT expansion stays on track. The company has the operational discipline to deliver (52-year track record, captive distribution, strong brands), but watch for any hint of volume softness or margin normalization in H2 — that's where the current bull case gets stress-tested. Until then, profit growth outpacing sales is the playbook.